Article info

Download PDFPDF

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Authors

  1. Correspondence to Dr Philip J Mease, Rheumatology Research, Swedish Medical Center, Seattle, WA 98122, USA; pmease{at}philipmease.com
View Full Text

Citation

Mease PJ, Smolen JS, Behrens F The SPIRIT H2H study group, et al
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Publication history

  • Received March 14, 2019
  • Revised July 23, 2019
  • Accepted August 29, 2019
  • First published September 28, 2019.
Online issue publication 
December 16, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.